Introduction
The renin-angiotensin system has an important role in the regulation of cardiovascular function. The primary active peptide hormone of this system is angiotensin II (Ang II). Angiotensin-converting enzyme (ACE) converts angiotensin I (Ang I) to Ang II and also inactivates bradykinin. One study demonstrated that ACE inhibition with captopril can provide myocardial protection during myocardial ischaemia and reperfusion. 1 Another study showed that the ACE inhibitor, ramiprilat, reduced infarct size and suggested that bradykinin played an important role in this myocardial protective action. 2 However, our previous studies showed that captopril and losartan both have cardiovascular protective effects in a rat model of ischaemia and reperfusion. Pretreatment with either losartan or captopril for 10 weeks increased the ventricular fibrillation (VF) threshold, decreased episodes of ventricular tachycardia (VT) and VF, and reduced myocardial infarct size.These effects were independent of haemodynamics. 3 The effect of a differing time course of pretreatment with the AT 1 -receptor antagonist, losartan, has not yet been investigated.
Vascular endothelial growth factor (VEGF) is a mediator of developmental and tumour-induced angiogenesis. In adult tissues and myocardial cell culture,VEGF is significantly increased by myocardial infarction and hypoxia. However, the effects of a differing time course of occlusion and reperfusion has not been investigated.
The objective of this investigation was to explore the effects of different durations of pretreatment with losartan on myocardial infarct size, haemodynamics, arrhythmias, VF threshold, endothelial function, and VEGF in a rat model of ischaemia-reperfusion.
Methods

Experimental groups
One hundred and four female Sprague-Dawley rats (body weight 225-250 g) were randomly divided into four groups : group C was a normal control; groups L-1d, L-1w and L-4w were given 40 mg/kg/day of losartan in drinking water for one day, one week and four weeks respectively. The rats were housed in a room maintained at a constant temperature and kept on a 12-hour lightdark cycle. All rats were fed a regular diet.
Rat model of acute myocardial ischaemia and reperfusion
A rat model of left coronary artery occlusion and reperfusion was used as previously described. 4 After induction of anaesthesia (pentobarbital, 40 mg/kg body weight intraperitoneally), a tracheostomy was performed and the animal was ventilated on a Harvard Rodent Respirator (Model 683, Harvard Apparatus). A reversible coronary artery snare occluder was placed around the proximal left anterior descending coronary artery (LAD) through a midline sternotomy. Rats in each group were subjected to 17 minutes of LAD occlusion and 120 minutes of re-flow. A plastic catheter (PE50) was inserted into the femoral artery to measure haemodynamics. Heart rate (HR), systolic pressure (SP), diastolic pressure (DP), and the product of HR and SP, were monitored by a MacLab/4S (Milford, MA).
Thresholds and effective refractory period (ERP)
Electrocardiograms (ECGs, lead I or II) were obtained by subcutaneously inserting needle electrodes into the limbs and were monitored during the ischaemia and reperfusion period. Ventricular fibrillation thresholds were measured before occlusion and after 1 hour of reperfusion. Electrodes were inserted about 1 mm into the right ventricular surface. Multiple electrical stimuli (50/second for 2 seconds) were applied and intensified by 0.1 MA each time using a Stimulator (Model DTU, Bloom Associates limited, Reading, PA). The threshold of VF from the right ventricle was assessed as the electrical intensity which induced VF. ERP measurement was obtained using 8 of S1 (100 ms) and followed by 1 of S2 (from 80 ms) stimuli. ERP from the right ventricle was assessed as the period (S1-S2) at which there was no response to S2 stimuli. No rat received anti-arrhythmics before or during the occlusion or reperfusion.
Infarct size
Infarct size was measured as previously described. 4, 5 The left coronary artery was reoccluded, and phthalocyanine blue dye was injected into the left ventricular (LV) cavity, allowing normally-perfused myocardium to stain blue. The heart was then excised, rinsed of excess dye and sliced transversely from apex to base into 2 mm thick sections. The sections were incubated in a 1% solution of triphenyltetrazolium chloride (TTC) for 10 to 15 minutes until viable myocardium was stained brick-red. Infarct-related myocardium fails to stain with TTC. The tissue sections were then fixed in a 10% formalin solution and weighed. Colour digital images of both sides of each transverse slice were obtained with a videocamera (COHU Y/C 460 HTYL, 768x494 array, Leica) connected to a microscope (Stereo Zoom 6 Photo, Leica), using the Rasterops Frame Grabber card and Frame Grabber 3.2 software (Rasterops). The regions showing blue-stained (nonischaemic), red-stained (ischaemic but non-infarcted) and unstained (infarcted) tissue were outlined on each colour image and measured using the program NIH Image 1.59 (National Institutes of Health) in a blinded fashion. On each side, the fraction of the LV area representing infarct-related tissue (average of two images) was multiplied by the weight of that section to determine the absolute weight of infarct-related tissue. The infarct size for each heart was expressed as:
Ang II and renin levels in plasma
After pretreatment, a subset of rats in the four groups (five rats selected at random from each group) were sacrificed by lethal injection with pentobarbital (130 mg/kg, intraperitoneally). At the time of death, blood was taken for measurement of plasma Ang II and renin by radioimmunoassay. Plasma renin activity was measured using an Ang I antibody, and expressed as nanograms of Ang I generated per ml plasma during a 2-hour incubation at 37°C and pH 6.5. Ang II concentration was measured after extraction on bentonite. The recovery of Ang II was 80%. 6, 7 Vascular reactivity studies Aortic ring segments (1 to 2 mm in diameter and 4 to 5 mm in length) were rapidly excised from the descending thoracic aorta for organ bath studies of vascular reactivity. Each ring was suspended horizontally between two parallel stainless steel wires to measure isometric force in individual organ baths containing Krebs solution at 37°C. Isometric force generated by the ring segment was recorded continuously as previously described. 8 Ring segments were stabilised at 1 G rest force for 60 minutes before being studied. Phenylephrine (Phe) in increasing doses, from 10 -9 to 10 -4 M, was added to each organ bath. For each ring, the dose needed to achieve half-maximal contraction (EC50 Phe ) was calculated. After the Phe contraction series, the baths were washed out three times with fresh Krebs solution and each ring allowed to stabilise for 1 hour.
For determination of endothelium-derived nitric oxide (NO)-mediated vasorelaxation, aortic rings, that had been precontracted with the EC50 Phe , were then exposed to acetylcholine (10 -9 to 10 -4.5 M). Acetylcholine induces vasorelaxation by release of NO that is coupled to muscarinic receptor stimulation. For measurement of endothelium-derived NO-mediated vasorelaxation induced by a non-receptor-dependent mechanism, aortic rings were exposed to the calcium ionophore (A23187) in increasing doses (from 10 -9 to 10 -4.5 M) after the rings had been precontracted by EC50 Phe and stable tension had developed. Lastly, each ring was precontracted and exposed to the endothelium-independent relaxation agent nitroglycerin (doses from 10 -9 to 10 -5 M).Vascular reactivity experiments were performed by an investigator who was blinded to the treatment groups.
VEGF study
Another 54 Sprague-Dawley rats were randomised to 18 groups:Sham as a control (each group had sham); Occlusion: 5, 10, and 17 minutes; with Re-flow: 0, 1, and 2 hours. After different durations of occlusion and reperfusion, the heart was excised. VEGF proteins in the ischaemic and non-ischaemic LV myocardium were measured by Western blot analysis. VEGF change was expressed relative to control (1.0).
Statistical analysis
All results are presented as mean±SEM. The 
Results
Haemodynamic data
There were no significant differences in heart rate, systolic pressure, diastolic pressure, and ratepressure product (an index of myocardial oxygen consumption) between the four groups at baseline, during coronary occlusion, or during reperfusion. The haemodynamic parameters in all rats declined during the course of the experiment.
Angiotensin II and renin levels in plasma
Rats treated with losartan for four weeks had significantly higher plasma levels of Ang II (groups L-4w, L-1w, L-1d vs. C : 90±37, 64±14, 53±14 vs. 13±3 pg/ml, p=0.046), as displayed in Figure 1 . The rats treated with losartan for four weeks had higher levels of plasma renin activity (203±39 vs. 23±10 ng/ml, p=0.006).
Threshold and ERP
The thresholds of VF before occlusion and after 1 hour of reperfusion were higher in the L-1w and L-4w groups compared with the control group C, but not significantly (1.15±0.47, 1.29±0.27 vs. 0.95±0.11 MA, p>0.05; 2.37±0.75, 1.12±0.27 vs. 1.24±0.19 MA, p>0.05). ERPs before occlusion and after 1 hour of reperfusion were not different between the four groups (L-1d, L-1w, L-4w vs. C: 34±2, 28±1, 31±2 vs. 31±1 MS; 32±2, 31±3, 30±1 vs. 30±1 MS, respectively).
Myocardial infarct size
Infarct size (Infarct mass/risk area and infarct mass/LV) was significantly smaller in the L-4w group compared with the control group C (38±6 vs. 55±3% and 23±4 vs. 31±2, p=0.010, 0.037 respectively), as displayed in Figure 2 .
Vascular reactivity
Only four weeks of pretreatment with losartan significantly increased maximal A23187-induced endothelium-dependent vasorelaxation (-81±4 vs.
-62±7%, p=0.039), as displayed in Figure 3 . There were no significant differences in maximal vasocontraction by phenylephrine and maximal vasorelaxation induced by acetylcholine or nitroglycerin among the four groups.
VEGF
Compared with sham control, VEGF in ischaemic myocardium was significantly increased after 10 and 17 minutes of occlusion (1.5 and 1.7 fold increase over controls, respectively), and significantly decreased after 1 and 2 hours of reperfusion, as displayed in Figure 4 . VEGF levels in ischaemic myocardium were significantly lower in groups L-4w and L-1w (0.58±0.10 and 0.75±0.50 vs. 1.0, p=0.001, 0.040 respectively), as displayed in Figure 5 .
Discussion
The present results provide new evidence of the cardiovascular protection of AT 1 -receptor antagonists. Our findings suggest that losartan has timedependent cardiovascular protective effects. Four weeks of pretreatment with losartan decreased myocardial infarct size and VEGF as a sensitive indicator of myocardial ischaemia, and increased endothelial-dependent vasorelaxation.
It is possible that the results of this study were influenced by the dose of drugs used. We attempted to use a dose which was effective but did not induce hypotension. In previous rat studies, the dose range of losartan was 50-60 mg/kg per day for 12 weeks 9,10 or 2 g/l drinking water for three weeks to one year. 11, 12 We did a preliminary dosefinding study. After one to two weeks of losartan, 60 mg/kg/day, haemodynamics (HR, SP, DP) did not change significantly in the four groups. The lower dose, 40 mg/kg/day for four weeks, was then selected to have a safety margin in avoiding significant changes in haemodynamics. In the present study, 40 mg/kg/day losartan for four weeks resulted in no change in HR, SP, DP, and HRxSP. There were no significant differences in haemodynamics between the four groups at any time point during 17 minutes of ischaemia and 2 hours of reperfusion. Therefore, we conclude that losartan reduced infarct size independently of haemodynamic effects.
The ACE inhibitor, ramiprilat (50 µg/kg, IV), reduced infarct size in a rabbit model of ischaemia/reperfusion. 2 This effect was abolished by pretreatment with the specific bradykinin-2 antagonist (HOE140, 1 µg/kg, IV) or by inhibiting NO synthase (L-NAME, 100 µg/kg, IV). 2, 13 This supports the role of improved endothelial function during reperfusion, which would limit infarct size. Furthermore, it would suggest that bradykinin and NO play a pivotal role. However, since losartan reduced infarct size, bradykinin cannot be the only mechanism of benefit. Reducing the adverse effects of Ang II must also play a role. The AT 1receptor anatgonist, losartan, was associated with a significant decrease in cardiac fibrosis in rats treated post-myocardial infarction. 14 ACE inhibition and AT 1 -receptor blockade were equally effective in limiting the increase in ventricular mass, suggesting that myocyte hypertrophy, the major determinant of ventricular mass, was strongly influenced through activation of the AT 1 -receptor. 15 Hypertension is associated with endothelial dysfunction, characterised by decreased endothelium-dependent relaxation and increased endothelium-dependent contraction. A study in spontaneously hypertensive rats showed that both captopril and losartan improved endothelial function in aortic rings, not only by enhancing endothelium-dependent relaxation but also by reducing contractions in response to an endotheliumderived contracting factor. 10 Both losartan and quinapril prevent endothelial dysfunction induced by triglyceride-rich lipoproteins in healthy volunteers. 16 Both enhanced formation of Ang II and enhanced metabolism of bradykinin might account for a vascular deficiency of bioactive NO. 17 The results of the present study showed that, after precontraction by the EC50 of phenylephrine, losartan increased calcium ionophore (A23187)induced endothelium-dependent vasorelaxation, but did not increase acetylcholine-induced vasorelaxation. Both acetylcholine and A23187 produce endothelium-dependent vasorelaxation. However, A23187 is receptor-independent and usually causes more vasorelaxation than the muscarinic receptordependent acetylcholine. It is likely that losartan improved endothelium-dependent vasorelaxation in rat aortic vascular smooth muscle in vitro by a mechanism other than selectively enhancing muscarinic receptor-mediated endothelial function.
VEGF is a mitogen for endothelial cells and also has the potential to increase vascular permeability factor (VPF). Ang II increases VPF/VEGF mRNA in a dose-dependent manner. This effect was blocked by pretreatment with losartan. 18 Exposure to Ang II induced a significant increase in VEGF mRNA and protein levels. However, the AT 1 -receptor antagonist, losartan, prevented Ang II-induced VEGF protein secretion. 19 The present results show that VEGF in ischaemic myocardium increased after occlusion and decreased after reperfusion.These data suggest that the VEGF level is a sensitive indicator of myocardial ischaemia. The results also showed that VEGF in ischaemic myocardium was significantly decreased after one and four weeks of pretreatment with losartan.
In summary, the AT 1 -receptor antagonist, losartan, had time-dependent cardiovascular protective effects. Four weeks of pretreatment with losartan reduced myocardial infarct size and increased endothelium-dependent vasorelaxation. As a sensitive indicator of myocardial ischaemia, VEGF increased after ischaemia and decreased after reperfusion. One and four weeks of pretreatment with losartan significantly decreased VEGF in ischaemic myocardium. These data suggest that losartan has anti-ischaemic effects in a rat model of ischaemia-reperfusion.
